Targeted therapy for advanced anaplastic lymphoma kinase (ALK )-rearranged non-small cell lung cancer

Overview of attention for article published in Cochrane database of systematic reviews, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 16 tweeters

facebook: 1 Facebook page

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 51 Mendeley

Summary Twitter Facebook Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

Article in Critical Reviews in Oncology/Hematology (May 2023)

Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature

Article in Clinical Hematology International (April 2023)

Mutation Status Analysis Of 58 Patients With Advanced ALK Fusion Gene Positive Non Small Cell Lung Cancer

Preprint in Research Square (March 2023)